创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

猴菇和胃颗粒治疗胃癌前病变的临床疗效及对炎症因子与免疫功能的影响

Clinical Efficacy of Hougu Hewei Granules in the Treatment of Gastric Precancerous Lesions and the Effects on Inflammatory Factors and Immune Function

  • 摘要: 目的 探讨猴菇和胃颗粒治疗胃癌前病变的临床疗效,以及对患者血清炎症因子与免疫功能的影响。方法 选取2023年1月至2025年1月广东省第二中医院收治的胃癌前病变患者102例,按照随机数字表法分为观察组与对照组,各51例。对照组口服胃复春片,观察组服用猴菇和胃颗粒,2组的疗程均为12周。比较2组治疗12周后的总有效率;分别于治疗前、治疗4周和12周后,比较2组中医证候积分、炎症因子白细胞介素-6 (interleukin-6,IL-6)、白细胞介素-8 (interleukin-8,IL-8)和肿瘤坏死因子-α (tumor necrosis factor-α,TNF-α)水平、免疫功能指标(CD3+、CD4+和CD4+/CD8+比值)变化;记录患者治疗期间不良反应发生情况。结果 观察组的治疗总有效率为90.20%,高于对照组的74.51%(P < 0.05)。2组在治疗4周和12周后的胃痛、胃胀和痛处拒按积分、IL-6、IL-8和TNF-α水平低于治疗前,CD3+、CD4+和CD4+/CD8+比值高于治疗前(P < 0.05),且2组在治疗12周后的中医证候积分、炎症因子水平低于治疗4周后,免疫功能指标高于治疗4周后(P < 0.05);观察组在治疗4周和12周后的胃痛、胃胀和痛处拒按积分、IL-6、IL-8和TNF-α水平低于对照组,CD3+、CD4+和CD4+/CD8+高于对照组(P < 0.05)。治疗期间,2组均未发生不良反应。结论 猴菇和胃颗粒对胃癌前病变患者的疗效显著,可有效改善患者中医证候,减轻机体炎症反应并调节免疫功能,具有临床推广应用价值。

     

    Abstract: Objective To explore the clinical efficacy of Hougu Hewei Granules in the treatment of gastric precancerous lesions, and its effects on serum inflammatory factors and immune function in patients. Methods A total of 102 patients with gastric precancerous lesions admitted to Guangdong Second Traditional Chinese Medicine Hospital from January 2023 to January 2025 were enrolled and divided into an observation group and a control group by random number table method, with 51 cases in each group. The control group took Weifuchun Tablets orally, while the observation group took Hougu Hewei Granules orally. The course of treatment was 12 weeks for both groups. The total effective rate was compared between the two groups after 12 weeks of treatment. The changes of traditional Chinese medicine (TCM) syndrome scores, levels of inflammatory factors interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α) and immune function indicators (CD3+, CD4+ and CD4+/CD8+ ratio) were compared between the two groups before treatment, after 4 weeks and 12 weeks of treatment. Adverse reactions during treatment were recorded in both groups. Results The total effective rate of the observation group was 90.20%, which was higher than that of the control group (74.51%) (P < 0.05). After 4 weeks and 12 weeks of treatment, the scores of stomach pain, bloating and pain aggravated by pressure, as well as the levels of IL-6, IL- 8 and TNF-α in the two groups were lower than those before treatment, while the percentages of CD3+ and CD4+, and the CD4+/ CD8+ ratio were higher than those before treatment (P < 0.05). The TCM syndrome scores and inflammatory factor levels of both groups after 12 weeks of treatment were lower than those after 4 weeks of treatment, and the immune function indicators were higher than those after 4 weeks of treatment (P < 0.05). After 4 weeks and 12 weeks of treatment, the scores of stomach pain, bloating and pain aggravated by pressure, and the levels of IL-6, IL-8 and TNF- α in the observation group were lower than those in the control group, while the percentages of CD3+ and CD4+, and the CD4+/CD8+ ratio were higher than those in the control group (P < 0.05). No adverse reactions occurred in either group during the treatment period. Conclusion Hougu Hewei Granules has significant therapeutic effect on patients with gastric precancerous lesions. It can effectively improve TCM syndromes, alleviate inflammatory response and regulate immune function, with good value for clinical application and promotion.

     

/

返回文章
返回